Pediatr Res
. 2026 May 5.
doi: 10.1038/s41390-026-05007-2. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/42082735/
Progress in cell therapies for neonatal conditions: Proceedings of the Third Neonatal Cell Therapies Symposium (2025)
Abdul Razak 1 2 3, Suzanne L Miller 3 4, Courtney A McDonald 3 4, Madison C B Paton 5 6, Sophie Sinistaj 7, Won Soon Park 8 9 10, Augusto Zani 11, Ishmael M Inocencio 3 4, Salvatore Pepe 12 13, Bobbi Fleiss 14 15, Pierre Gressens 15, Tim Wolfs 16 17 18, Nancy Messino 3, Hannah Tribe 14, Atul Malhotra 19 20 21
Affiliations Expand
- PMID: 42082735
- DOI: 10.1038/s41390-026-05007-2
Abstract
This special article synthesizes transformative insights from a recent international neonatal cell therapy symposium (held in Noosa, Australia) where leading experts convened to explore regenerative solutions for serious perinatal and neonatal conditions. The discussions highlighted pioneering cell-based therapies targeting preterm brain injury, bronchopulmonary dysplasia, fetal growth restriction, hypoplastic left heart syndrome and congenital diaphragmatic hernia; neonatal conditions that present both neonatal challenges and long-term morbidities, demanding innovation beyond conventional medical, surgical and supportive care. Advances in regenerative medicine, particularly those leveraging umbilical cord blood-derived cells, mesenchymal stromal cells from various sources, amniotic fluid and human amnion epithelial derived cells and extracellular vesicles, are redefining therapeutic possibilities through paracrine signaling, immunomodulation, and tissue repair to counteract shared mechanisms of inflammation, oxidative stress, apoptosis, and impaired regeneration. This article integrates the symposium’s key clinical and translational perspectives, emphasizing system-specific developments across cardiovascular, pulmonary, neurological, and systemic domains, with a particular focus on scalable production strategies, and the importance of multidisciplinary collaboration. IMPACT: Synthesizes global evidence from preclinical and clinical studies to define the current translational trajectory of cell therapies across major neonatal conditions. Highlights integrative frameworks combining advanced preclinical modeling, clinical trials, scalable manufacturing and stakeholder collaboration to accelerate translation in neonatal regenerative medicine.
© 2026. The Author(s).
About The Author
